viewWattle Health Australia Ltd

Wattle Health Australia delivers record sales as it broadens its product range and enters new markets

Wattle is also expanding into new markets, having made its first sales in Macau and India in the March quarter.

Picture of bottles of milk
Sales growth in Australia and overseas has been assisted by high-profile distribution agreements

Wattle Health Australia Ltd (ASX:WHA) has requested a suspension in trading of its securities, but not before it released some impressive March quarter sales figures.

The company issued a statement around midday, saying that it would be releasing an announcement regarding the finalisation of a joint venture and/or potential capital raising.

The voluntary suspension will remain in place until April 20, 2018, or at such time as the company has finalised its joint-venture or capital raising initiatives.

Strong sales growth

In the three months to March 31, 2018, Wattle’s range of dairy and nutritional products generated gross sales of $804,379.

This was a particularly strong performance given that it represented 121% of total sales for the six months to December 31, 2017.

Importantly, the company is growing its sales in Australia and overseas assisted by high-profile distribution agreements.

Metcash, API and Tesco among distributors

In Australia, the company’s distributors include Metcash (ASX:MTS), Australian Pharmaceutical Industries (ASX:API) and JR Duty Free.

The company has three major distributors in China, including Tesco Lotus Supermarket.

Wattle is also expanding into new markets, having made its first sales in Macau and India in the March quarter.

Adds new products and breaks into new markets

The company has broadened its product range, adding nutritional dairy products pitched at seniors, nursing mothers and students.

In February, Wattle acquired 80% of organic baby skincare company Little Innoscents for $300,000 in cash and $400,000 in shares.

It has a range of products made from 100% natural, organic and botanical ingredients.

The group is already profitable, generating underlying earnings of $250,000 from revenues of $900,000 in fiscal 2017.

Its products are distributed through 700 stores in Australia and exported to markets in the Middle East and South East Asia.

Quick facts: Wattle Health Australia Ltd

Price: - AUD

Market: ASX
Market Cap: -

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Full interview: TRACON Pharmaceuticals reveals its low-cost drug development...

TRACON Pharmaceuticals (NASDAQ:TCON) CEO Charles Theuer tells Proactive the biotechnology company ended 2019 with cash, cash equivalents and short-term investments of $16.4 million. Theuer explains despite engaging in five different clinical trials, three of the five company's clinical trials...

19 hours, 2 minutes ago

2 min read